Similar articles

• Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.

  Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, Van Doorn PA, De Jong G, Hop W, Smit GP, Shapira SK, Boer MA, van Diggelen OP, Reuser AJ, Van der Ploeg AT. Winkel LP, et al. Ann Neurol. 2004 Apr;55(4):495-502. doi: 10.1002/ana.20019. Ann Neurol. 2004. PMID: 15048888
• A randomized study of alglucosidase alfa in late-onset Pompe's disease.

  van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA. van der Ploeg AT, et al. N Engl J Med. 2010 Apr 15;362(15):1396-406. doi: 10.1056/NEJMoa0909859. N Engl J Med. 2010. PMID: 20393176 Clinical Trial.
• Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.

  Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, van der Ploeg AT. Winkel LP, et al. Muscle Nerve. 2003 Jun;27(6):743-51. doi: 10.1002/mus.10381. Muscle Nerve. 2003. PMID: 12766987
• Late-onset Pompe's disease.

  Teener JW. Teener JW. Semin Neurol. 2012 Nov;32(5):506-11. doi: 10.1055/s-0033-1334469. Epub 2013 May 15. Semin Neurol. 2012. PMID: 23677658 Review.
• [Pompe's disease. Part II. Treatment strategies and enzyme replacement].

  Illés Z, Várdi Visy K. Illés Z, et al. Ideggyogy Sz. 2009 Sep 30;62(9-10):299-307. Ideggyogy Sz. 2009. PMID: 19835271 Review. Hungarian.